Drug Discovery in Space: Applications and case studies
27 January, 2022

Organized by the Japan Manned Space Systems Corporation and InnoStudio, the first ever webinar series dedicated to pharmaceutical research and drug discovery in space, with both scientific and commercial aspects, is now bringing you the newest results and excellent presentations from this emerging field.

The second part of this series ”Applications and case studies” will be held on January 27, Thursday 6 PM CET and will include two presentations by internationally renowned experts with the following topics:

  1. Beyond the ISS: The World’s First Commercial Space Station – New markets in LEO including pharmaceutical & technology products
  2. The advantages of protein crystallization in space


REGISTER FOR FREE HERE: https://drugdiscoveryinspace.com/registration/

For more information about the speakers and the program of the full webinar series visit our website at: https://drugdiscoveryinspace.com/


Upcoming Events

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Social Media

Follow our daily updated Social Media pages for the latest news, event,curiosities and fun.

Latest News & Events

Latest Articles

InnoStudio is cited in the C&EN article “Pharma goes to Space”

InnoStudio is cited in the C&EN article “Pharma goes to Space”

C&EN article by Shi En KimNovember 13, 2022 | A version of this story appeared in Volume 100, Issue 40 IN BRIEF: The lack of gravity in space opens up unique opportunities for drug design and development. With the influx of commercial entities providing access to...

Hungarians develop more effective COVID drugs in space

Hungarians develop more effective COVID drugs in space

Published May 7, 2021 on 24.hu In the last few months, in addition to vaccine developments against the coronavirus, little has been heard of regarding what efforts have been made to develop new medicines for the treatment of already covid infected patients. Regarding...